How to update a living systematic review and keep it alive during a pandemic: a practical guide
- PMID: 37660117
- PMCID: PMC10474670
- DOI: 10.1186/s13643-023-02325-y
How to update a living systematic review and keep it alive during a pandemic: a practical guide
Abstract
Background: The covid-19 pandemic has highlighted the role of living systematic reviews. The speed of evidence generated during the covid-19 pandemic accentuated the challenges of managing high volumes of research literature.
Methods: In this article, we summarise the characteristics of ongoing living systematic reviews on covid-19, and we follow a life cycle approach to describe key steps in a living systematic review.
Results: We identified 97 living systematic reviews on covid-19, published up to 7th November 2022, which focused mostly on the effects of pharmacological interventions (n = 46, 47%) or the prevalence of associated conditions or risk factors (n = 30, 31%). The scopes of several reviews overlapped considerably. Most living systematic reviews included both observational and randomised study designs (n = 45, 46%). Only one-third of the reviews has been updated at least once (n = 34, 35%). We address practical aspects of living systematic reviews including how to judge whether to start a living systematic review, methods for study identification and selection, data extraction and evaluation, and give recommendations at each step, drawing from our own experience. We also discuss when it is time to stop and how to publish updates.
Conclusions: Methods to improve the efficiency of searching, study selection, and data extraction using machine learning technologies are being developed, their performance and applicability, particularly for reviews based on observational study designs should improve, and ways of publishing living systematic reviews and their updates will continue to evolve. Finally, knowing when to end a living systematic review is as important as knowing when to start.
Keywords: Covid-19; Epidemiology; Public health; Research design.
© 2023. BioMed Central Ltd., part of Springer Nature.
Conflict of interest statement
NL declares that her institution has received funding from the Swiss National Science Foundation (176233) and the European Union Horizon 2020 research and innovation programme — project EpiPose (grant agreement number 101003688). The other authors declare that they have no competing interests.
Figures



Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Experience report of two living systematic Cochrane reviews on COVID-19.Z Evid Fortbild Qual Gesundhwes. 2024 Mar;184:90-95. doi: 10.1016/j.zefq.2023.11.004. Epub 2024 Jan 13. Z Evid Fortbild Qual Gesundhwes. 2024. PMID: 38220533
-
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2020 Jul 10;7:CD013600. doi: 10.1002/14651858.CD013600.pub2. PMID: 32406927 Free PMC article. Updated.
-
Methodological challenges for living systematic reviews conducted during the COVID-19 pandemic: A concept paper.J Clin Epidemiol. 2022 Jan;141:82-89. doi: 10.1016/j.jclinepi.2021.09.013. Epub 2021 Sep 12. J Clin Epidemiol. 2022. PMID: 34525406 Free PMC article.
-
Coronavirus disease (COVID-19) pandemic: an overview of systematic reviews.BMC Infect Dis. 2021 Jun 4;21(1):525. doi: 10.1186/s12879-021-06214-4. BMC Infect Dis. 2021. PMID: 34088271 Free PMC article. Review.
Cited by
-
Delivering rapid, up-to-date, high-quality evidence is feasible during health emergencies: PAHO living systematic review of 305 COVID-19 potential therapeutics.Rev Panam Salud Publica. 2025 Apr 28;49:e41. doi: 10.26633/RPSP.2025.41. eCollection 2025. Rev Panam Salud Publica. 2025. PMID: 40297218 Free PMC article.
-
Methods for conducting a living evidence profile on mpox: An evidence map of the literature.Cochrane Evid Synth Methods. 2024 Feb 22;2(2):e12044. doi: 10.1002/cesm.12044. eCollection 2024 Feb. Cochrane Evid Synth Methods. 2024. PMID: 40475807 Free PMC article.
-
Cochrane's COVID-19 Living Systematic Reviews: A Mixed-Methods Study of Their Conduct, Reporting and Currency.Cochrane Evid Synth Methods. 2025 Mar 28;3(3):e70024. doi: 10.1002/cesm.70024. eCollection 2025 May. Cochrane Evid Synth Methods. 2025. PMID: 40656451 Free PMC article.
-
Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation.BMJ. 2024 Nov 19;387:e079183. doi: 10.1136/bmj-2024-079183. BMJ. 2024. PMID: 39562017 Free PMC article.
-
Operationalization of Artificial Intelligence Applications in the Intensive Care Unit: A Systematic Review.JAMA Netw Open. 2025 Jul 1;8(7):e2522866. doi: 10.1001/jamanetworkopen.2025.22866. JAMA Netw Open. 2025. PMID: 40699572 Free PMC article.